Hepatitis C (HCV) is the first virus to be discovered by molecular cloning without direct use of biological or biophysical methods. HCV was first recognised in 1974 as non-A, non-B (NANB) hepatitis
resulting from blood transfusions. It took almost 15 years to identify it successfully -by detecting a clone in a library of cDNA prepared from the nucleic acids extracted from plasma known to be infectious for chimpanzees. The clone was derived from a positive-sense RNA of about 10 000 nucleotides, with a long open reading frame encoding for a polyprotein of about 3000 amino acids. The structure of the RNA and the encoded polyprotein had properties similar to known flaviviruses and pestiviruses. Functions of viral proteins produced by proteolytic cleavage of the polyprotein are estimated by analogy with known viruses of similar genomic organisation. Each of the HCV proteins has been produced in recombinant organisms and used as an antigen in immunoassays to investigate serological responses during the course of infection. Seroconversions to both structural and non-structural antigens are observed during the course of disease but typical diagnostic serological patterns have not yet evolved. Immunoassays for HCV antibodies reacting with recombinant antigens are used widely for screening blood donations and for studying the epidemiology of HCV infection. Comparisons of the nucleic acid sequences from different isolates of HCV have shown considerable variability throughout the genome. The importance of this genomic heterogeneity will be a challenging problem for the future. were used extensively but failed to detect hepatitis C virus (HCV). During this period the disease was characterised as a long term, persisting infection, that was initially mild and asymptomatic. Serious chronic liver diseases developed progressively over a period of years. The breakthrough came through molecular cloning of the nucleic acids extracted from chimpanzee plasma containing a high degree of NANB hepatitis infectivity.2 The sequence of the first identified clone encoded a 55 amino acid peptide containing an immunodominant epitope that reacted only with antiserum from NANB hepatitis patients. 3 The sequence of a positive strand RNA of about 10 000 ribonucleotides was determined eventually by overlapping clones, and was designated the HCV genome.' Our current knowledge of HCV is extensive, derived exclusively from studying the clinical nature of the disease and from the information encoded within the genomic sequence.
Genomic organisation
The organisation of the HCV genomic RNA is illustrated in Figure 1 . The original isolate (HCV-1) was a positive-sense RNA of 9401 ribonucleotides, containing a poly-A tail at the 3' end. The sequence contained a 5' untranslated region of 341 bases, followed by a long open reading frame encoding for a polyprotein of 3011 amino acids, and a 3-untranslated region of about 27 bases. This RNA structure is similar to that of the well known flaviviruses that infect both animals and humans. The calculated hydrophobic/hydrophilic properties of the HCV encoded polyprotein are similar to typical flaviviruses and pestiviruses. Based on analogy with these viruses the probable cleavage points of the HCV polyproteins are indicated in Figure 1 . The indicated size and function of the viral proteins are supported by in vitro translation of HCV-RNA and characterisation of the translation products.5 Consistent with the known functions of most flavivirus proteins, the three N-terminal HCV proteins are probably structural (C, El, E2/NS1), and the four C-terminal proteins (NS2, NS3, NS4, NS5) function for viral replication. Growth of HCV in culture will be necessary for the final confirmation of the function of the proteins. A hypervariable region has been identifed at the N-terminal region of the E2/NS 1 cleavage protein (Fig 1) . Every reported genomic sequence has a different amino acid sequence within the region of amino acid 384-408 of the polyprotein. (10) compared with more than 20% for the nonstructural proteins. The C protein was found to be the most immunogenic in this example, different serotypes, escape mutants, population. In this group of seropositive pathogenic/non-pathogenic strains, duration donors, the various antibodies were distributed of infection, cross neutralisation, multiple as follows: core (94%), El (44%), E2/NS 1 reinfections, cell tropism. Further studies with (38%), NS4 (75%), and NS5 (69%). Thus, no patients to correlate HCV sequence hetero-one antibody would identify all infections. geneity with disease severity, epidemiology, Further analyses indicated that all HCV treatment, or prophylaxis may elucidate this.
infections in these donors could be identified with a combination of C, NS3, and NS4 recombinant antigens. Commercial tests have Immunobiology been configured with these three antigens and Recombinant HCV proteins (produced in are used widely to identify and interdict bacteria, yeast, or mammalian cells) and seropositive blood from transfusion services. synthetic peptide epitopes have been used in HCV screening has made significant contribimmunoassays to evaluate the immunogenicity utions to the safety of blood. The screening test of each of the viral proteins. Seroconversions has also been useful in epidemiological studies, to each viral protein have been observed identifying the agent in a large percentage of throughout the course of infection but without sporadic NANB cases of hepatitis. a unique and consistent serological pattern. history, however, the studies showed early /^,~seroconversion to non-structural proteins, without seroconversion to the core protein for _ --more than one year (Fig 3) . A serological The viral proteins have been produced in recombinant organisms and partially characterised, both biophysically and serologically. The infection can be identified and asymptomatic carriers prevented from making blood donations. Initially, most HCV infections are mild or asymptomatic but they can lead to serious chronic liver diseases over a period of many years. Prevention of new infections and successful treatment for those already infected may, in time, lead to control of this worldwide health problem. Although molecular studies can teach us much about the virus, our complete understanding can be accelerated through the growth of HCV in cell culture and visualisation by electronmicroscopy. A combination of molecular, clinical, and virological studies will be needed to answer many pressing questions about HCV infection, namely:
Is there ever recovery from infection followed by persisting immunity?
Is there an immunological basis for passive or active immunity?
What is the molecular basis for association with hepatocellular carcinoma after long term HCV infection?
What is the basis for the long persistence of HCV infection?
What is the major risk factor for sporadic HCV infection?
Are there transmission vectors for HCV infection?
Is there another blood borne hepatotropic virus?
Progress has been considerable since the HCV genome was identified by molecular cloning, but there are still more questions than answers. Hopefully, in this era of molecular genetics, many of these answers will be apparent before we know what HCV actually 'looks' like.
